Neurogene (NASDAQ: NGNE) — Perfil da empresa, notícias e dados financeiros
Neurogene develops gene therapy treatments for nervous system disorders utilizing AAV vectors for targeted delivery.
Neurogene
Neurogene (NASDAQ:NGNE) is a biotechnology company developing gene therapy treatments for nervous system disorders. They utilize adeno-associated virus (AAV) vectors to deliver corrective genetic material to target cells, potentially offering a new approach to treating neurological conditions. Neurogene's pipeline might focus on treatments for rare or debilitating diseases with limited therapeutic options. While they are still in the pre-commercial stages, with clinical trials ongoing, Neurogene's gene therapy research holds promise for offering life-changing treatments for patients with neurological conditions.
Resumo
Operações
Produtos e/ou serviços de Neurogene
- Adeno-associated virus (AAV) based gene therapy for neurological diseases, aiming to address genetic disorders by delivering normal genes to patients' cells.
- Development of a gene therapy for Aspartylglucosaminuria (AGU), a rare lysosomal storage disease, focusing on reducing the accumulation of glycoasparagines.
- Gene therapy targeting Charcot-Marie-Tooth Disease, specifically focusing on mutations in the GJB1 gene, aiming to restore normal nerve function.
- Exploration of therapies for Rett Syndrome, a neurodevelopmental disorder, focusing on correcting MECP2 gene mutations.
- Next-generation sequencing (NGS) diagnostics for early identification of rare neurological genetic disorders, enabling timely intervention.
- Engagement in educational initiatives for the broader community about rare neurological genetic disorders, aiming to raise awareness and support affected families.
equipe executiva do Neurogene
- Rachel L. McMinnFounder, Executive Chair & CEO
- Christine Mikail CvijicPresident, CFO & Director
- Julie JordanChief Medical Officer
- Stuart CobbChief Scientific Officer
- Lina LiExecutive Director of Investor Relations
- Donna M. Cochener-MetcalfeSenior VP, General Counsel & Corporate Secretary
- Andrew E. MulbergSenior VP of Regulatory Affairs, Quality Assurance & Quality Control
- Ricardo JimenezSenior Vice President of Technical Operations
- Arvind SreedharanSenior Vice President of Business Operations
- Christina ShaferChief Commercial Officer
Principais indicadores financeiros
Resultados divulgados pela Neurogene, em USD.
- Cap. de mercado
- 540,1 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -5.0
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -103,2 mi | -90,4 mi | |
| 925 mil | -82,6 mi | -75,1 mi | |
| 0 | -55,6 mi | -36,3 mi | |
| 0 | -56,5 mi | -55,2 mi |